PEDIATRICS Vol. 82 No. 2 August 1988, pp. 283
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DASHEFSKY, B.
Right arrow Articles by GREEN, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DASHEFSKY, B.
Right arrow Articles by GREEN, M.

Ribavirin Use Questioned

BARRY DASHEFSKY MD1, ELLEN R. WALD MD1, and MICHAEL GREEN MD1

1 Department of Pediatrics, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, PA 15213

To the Editor.—

The report by McMillan and colleagues1 of the nonpredictiveness of certain clinical and laboratory tests in determining the duration of hospitalization of patients with respiratory syncytial virus adds to our understanding of this important respiratory pathogen. However, we disagree with the authors' implied assumption that ribavirin therapy might be expected to shorten hospitalization and with their concluding recommendation "to institute aerosolized ribavirin therapy for essentially all infants with documented respiratory syncytial virus infection who require hospitalization."1(p26)